Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.41 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1372805 | 0.92 | MAOA (0.50) | TRPV1TAS1R3TAS1R1TAS1R2MAOA | |
| SCHEMBL7942829 | 0.92 | MAOA (0.50) | TRPV1TAS1R3TAS1R1TAS1R2MAOA | |
| SCHEMBL3300984 | 0.92 | MAOA (0.50) | TRPV1TAS1R3TAS1R1TAS1R2MAOA | |
| SCHEMBL29372292 | 0.90 | TAS1R3 (0.48) | TRPV1TAS1R3TAS1R1TAS1R2LMNA | |
| SCHEMBL15074697 | 0.88 | LMNA (0.48) | TAS1R3TAS1R1TAS1R2LMNAMEN1 | |
| SCHEMBL10256440 | 0.86 | LMNA (0.51) | LMNACTSSMEN1KMT2ATAOK1 | |
| SCHEMBL397521 | 0.86 | NR1H2 (0.42) | TAS1R3TAS1R1TAS1R2LMNACTSS | |
| SCHEMBL26073271 | 0.86 | TAS1R3 (0.45) | TRPV1TAS1R3TAS1R1TAS1R2LMNA | |
| SCHEMBL20683057 | 0.86 | TAS1R3 (0.45) | TRPV1TAS1R3TAS1R1TAS1R2LMNA | |
| SCHEMBL803449 | 0.85 | HTT (0.47) | TAS1R3TAS1R1TAS1R2LMNACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010108059-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR | INCYTE CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010108059-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR | INCYTE CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | HRH4, HRH2, HRH1 | TRPV1 6/4885TAS1R3 981/4885TAS1R1 785/4885 |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | HRH4, HRH2, HRH1 | TRPV1 7/4885TAS1R3 1418/4885TAS1R1 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.